Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
looking forward to the newsflow libero - hope they treat each as an individual RNs and not wrap them u[ in a single update as they are prone to do. if they released regular newsflow it would bring in new interest and actually speed up the leaving of the seller.
We hope the penny will drop and been hoping that since 2016 when BE was created. Every article i read on battery storage now mentions largo instead of us. We are supposed to be the central cog of this whole sub sector yet it is a ghost town for comms. For the record i firmly believe that BE will win part of the world bank tender but comms is not just poor here it is absolutely abysmal. A monthly update would do wonders just saying we have shipped x at a price of x and vamteco/vanchem ae running well. It is not rocket science and would reinforce that there is a london listed company that is doing well from the vanadium price resurgence. It is not as if we are a junior in this space, we control 50% of the world's primary production facilities. With this level of comms we could then forgive a little on the lack of BE comms but that could be simply covered with a sold x to the sector for use in VRFB's.
my posts were presented well with no typos (wonder!!) and got straight to the point.
so our vanadium price is increasing, other miners are giving out record dividends yet we labour. seems Fm needs to start with the basics - remind the market that we sell vanadium, a structural deficit exists and our commodity price is increasing. Seems Largo can manage it. Christ even Largo's VRFB platform looks like it is worth more and is what 3 months old - we are 5 years in with nothing to show for it. Really is time to step up and deliver.
i am not employed by BMN to do their PR, i am an investor wanting the business i invested in to succeed. at present it is not from the metric of shareholder returns.
funnily enough i do plenty of work in PR but when i email them they never respond. maybe you could email them or have a word in their ear at the next vanitec meeting!
I raise valid concerns that are shared by everyone on this board, including you.
as a long term investor i am not interested in running away i am seeking improvement from the board as i am sure you are because every point i made is valid and without hyperbole.
you would have thought so but increasingly FM is the mug in the room and we the investors are paying the price. Our commodity price is flying high yet our SP languishes far below any rational value because consistently he gets investors of funders on board who get their shares and sell almost immediately acting as a log term drag on the SP and it does seem that he is acutely aware of the sh*t that is AIM and almost now refuses to get involved hence the lack of comms. You can be pretty sure that we will not hear from BMN until the Q1 update which will be 6 weeks after the end of the quarter rendering it pretty much useless as a gauge of where the company is. We have had snippets of information on lemur and BE for years but actually no progress. the document found yesterday about projects in sao tome, uganda etc is a case in point - what are or were those projects. they are beginning to look the public sector in this country - talk, talk and no action. dividend, jse listing, the list of mistakes outshines the vametco style deals that he was lauded for in 2018.
i expect an RNS tomorrow on Abengoa. the contract would have an insolvency clause in it meaning much of the work done can be novated to BE. nevertheless i would expect a delay on delivering the mini grid which we should be told about.
should we not get an RNS i will be emailing chika and the NOMAD etc straightaway.
maybe they will put in the Q1 update when that comes out in May!!!
Been down a youtube rabbit hole on infrastructure today and what is really clear is that american infrastructure like bridges, railways etc are deteriorating at a rapid rate. The americans are not shy about studying how the chinese prioritise infrastructure when economic difficulties arise - build as it creates employment and improves productivity the two drivers of growth. So put into the context of global demand for vanadium - there is not a country untouched by the pandemic and with established thinking fully aligned with building infrastructure in recessions you have a world needing steel, hence current record prices for steel, and with countries in the west already requiring high vanadium content and the developing world pushing for enhanced content - you have a genuine perfect storm if you have the world's best grade and highest reserves of vanadium. Then add in the world's insatiable demand for green energy and the world's safest, most efficient and cost effective storage method. If you want vanadium you need to come to the Bushveld. FM - go and tell this story
We clearly have sellers be they duferco and/or orion and we have continually had deals done by FM that result in large numbers of shares being given out that are then used to provide a regular flows of sells which dampen the price. This is no MM game just simply supply outweighing demand. The lack of demand is because our CEO, albeit a phenomenal startegic thinker and dealmaker, is either a CEO who does not understand AIM and the need to provide regular newsflow or has a complete disregard for the SP and thus the shareholders hence II's walking further adding to the supply of shares in the market. the result is a scenario where we hear very little and quite often months without any news and as a result negative returns for SH. There is no doubt in my mind that quite frankly enormous news is around the corner but this needs to come with a rebrand to an energy focussed outfit, listing in JSE and main markets and a concerted comms strategy that includes the mainstream press. The mistakes thus far are really quite poor - dividend, JSE etc etc. One hopes that when the world bank deal lands it is alongside some serious investment in getting the story out there. Bushveld is not a tinpot share, it has world class assets and a decent valuation and a central place in quite possibly the biggest investment opportunity of a lifetime - green tech. The problem is nobody knows about it.
https://www.ft.com/content/a37d0ddf-8fb1-4b47-9fba-7ebde29fc510
This is probably the best article you will read this year. The opportunity for South Africa and Bushveld is absolutely enormous and once you read the article you will realise that is not hyperbole. Everything is moving super fast in the renewables sector and bushveld really do need to shout about it and rebrand, re list to make the green angle shine.
have you a ink to the GC video? thanks busy
no video or quote from GC - he is too busy fielding calls from the majors.
Remember what this does is proves the delivery concept, which is patented, which will be used in our trials for some of the worlds biggest and most valuable markets. monoclonal antbodies represent 7 of the top 10 markets in the world.
Outside of covid this is beyond enormous.
If the delivery method works for Covid then that is simply enormous for pharma. it is clear TILS are chasing the biggest markets - if the tech works the resultant value is staggering. There are atleast 5 NDA's and trials with third parties - no doubt the pharma industry is very excited about what TILS have.
The fact is we are well known to big pharma. Kunwar regular talks of big pharma and with ‘several ndas’ with them so far for our blockbuster drugs, we can expect heavy newsflow up to Q2 2021 Phase II trials commencing and if they go well then expect big names to be circling.
The covid story has legs. Sanofi/Regeneron (who have we just employed!!!!) and Roche have all hit difficulties with their drugs which makes TZLS 501 a candidate for therapeutic work and especially with our patent for oral and nasal delivery applicable to remdesivir, TILS are well placed to work with these groups. Any sniff of big pharma involvement will set this share price alight.
TILS have patents on oral and nasal formulation which is important as some diseases will be easier to target/respond better if given in different manners. Either way this is far superior to the high toxicity and high cost attributed to intravenous delivery. The IP has been developed with Dr Howard Weiner, sits on the TILs board, who runs the Ann Romney Center at Harvard and is one of the top 5 minds on MS globally ie when he speaks people listen.
Focussing on the two sectors that TILS have identified in conjunction with big pharma. These phase 2 trials start in July 2020 with results in Q2 2021.
Crohns – our CDA partner on this indication have said they want to Phase II orally administered Foralumab– worth $3.8bn in 2016 and anticipated to be $4.7bn by 2025 – major players in the treatment include Abbvie, Pfizer, J&J, Allergan.
MS – our CDA partner have said they want to Phase II nasally administered Foralumab - worth $20.83bn in 2019 and the drugs are high cost and are lifelong as there is no cure. Novartis, Sanofi, Roche, Merck, Pfizer. There have been major corporate moves in this sector in recent years – Receptos invented Ozanimod which was approved in March 2020 for MS and Receptos were taken over by Celgene for $7.2bn in 2015 (Celgene then were taken over by Bristol Myers Squibb for $74bn largest ever TO in pharma). This shows that big pharma is willing to take a long view and acquire early if the early trials are positive.
It has also been discovered that Foralumab could work in the Alzheimers market (£17.7bn per annum and a growth rate of 12.3% annual.
TILS amongst their 256 patents have a patent for the oral/nasal administration of Foralumab which is transformational for the sector.
"The issuance of this first-ever patent on formulation for oral administration of mAbs is a very exciting and timely development, as it facilitates a transformational avenue for immunotherapies" commented Dr. Howard L. Weiner, Chairman of Tiziana's Scientific Advisory Board
I have written a short piece on why foralumab in conjunction with our delivery technology and patent is the 'crown jewel' in TILS, our current value will be truly dwarfed by Foralumab.
Foralumab is the only fully human (as opposed to humanised which comes from mice thus making it easier to get approved on and means that humans produce less immune response to it so it works better) anti CD3 (attaches to t cells as part of the immune system) monoclonal antibody in clinical development anywhere in the world. Historically Anti CD3 have led to greater toxicities which has been a problem, TILS have the solution and this has been through a safety trial with no issues) It has potential to be used in autoimmune and inflammatory diseases including Crohns, MS, type 1 diabetes ($25bn annual market), Inflammatory bowel disease ($15.9bn annual market), psoriasis and arthritis ($8.6bn annual market), CV19.
GC calls foralumab the tiziana ‘crown jewel’ as it targets the largest markets in pharma. GC talks of Roche and Biogene having blockbuster drugs in the MS field. Foralumab is a monoclonal antibody a class of drugs which has been shown to be the greatest revenue generator in pharma full stop. 7 of the top 10 biggest revenue generators in pharma in 2019 were monoclonal antibodies and monoclonal antibodies in 2019 generated $122bn in turnover and by 2024 this is estimated to exceed $200bn a year. These drugs are given intravenously ie they get put into the body in a non targeted way but TILS have a patent and the technology to deliver orally, nasally and in lung which reduces toxicity and is more targeted. Apply that tech to a $100bn+ market a year and you have a major, major breakthrough with TILS leading it alongside what GC reckons are multi billon dollar a year turnovers for our targets if successful.
be interesting to note how many times Dr Kunwar says mothers milk tomorrow. when the PR increases with TILS the SP rises - simple as.
really interesting thoughts H-Hi. The drug Regeneron are using is via an IV which is more expensive and not as effective as our patents on oral, nasal and by lung. the contract is over $2bn imagine how a government would react if the effectiveness of the treatment was enhanced and the cost lower because of an innovative technology. mind boggles how we are worth £300m. what will the trigger be to get a big pharma to open serious talks - our brazil test uses the delivery system!!!! 2021 is looking super for TILS
TILS recently submitted two abstracts which summarised these validation studies, which were selected for presentation at the American Society of Clinical Oncology's 2020 Virtual Conference held in June. This is an exceptional achievement given ASCO’s selectivity. Furthermore, the conclusions shown were that StemPrintER provided a superior and more refined tool compared to the standard Oncotype DX.
In terms of getting STEM to market it requires the following:
- A validation study for a laboratory developed test – this should take 6 months which aligns with being able to go to market in early 2021 – as suggested by GC
- Take up by practitioners but by virtue of the current advocates who STEM have been working with you (major oncology centres, leading figures in oncology and leading hospitals – hence the ASCO abstract and poster) would think this backing alongside a test providing 40% better accuracy, oncologists would need little in the way of persuasion to move
- Getting the distribution channels lined up
The commercial prospects for StemPrintER look very buoyant given the size of the unmet need, the projected addressable market, as well as its superiority to a market standard, if a validation study confirms this promise.
Some key facts
2m new cases of breast cancer a year globally, 300,000 in the US.
It is important to understand that the exact sciences $2.8bn purchase of genomic healthcare also included a colon and prostate test. However, on a revenue basis in 2018, the breast cancer division contributed 89% of revenue to genomic healthcare so as a comparative figure, we can crudely say that the breast cancer division was worth $2.5bn of the purchase price.
Exact think the breast cancer diagnostic market is worth $1bn globally a year with 50% of that in the US. There is more than enough space for STEM, Oncotype DX and the other players to co-exist and for STEM to get a large slice of this growing market.
Exact are definitely driving their new asset as expecting $1.2bn profit this year against $900m in 2019. This is a 75% gross profit margin. If as I crudely put the breast cancer side is worth 90% of this then Exact should be extremely worried at how within a short timeframe their revenue could be shot to pieces by a new player – think yahoo getting usurped by Google – yes it still exists but not in any way, sense or shape as a competitor.
From an investor perspective lets say that STEM lists at 10% of the value of $2.8bn so $280m, we would need to wait 6-12 months for major milestones to be hit ie the retrospective test and distribution channels being sorted for the test to be then worth as a minimum $2.5bn but with a major upside from there.